A Study of GWP42006 in People With Focal Seizures - Part A

• ClinicalTrials.gov Identifier: NCT02369471
• Recruitment Status: Completed
• First Posted: February 24, 2015
• Last Update Posted: June 6, 2016
• Sponsor: GW Research Ltd
• Information provided by (Responsible Party): GW Research Ltd

Study Description

Brief Summary:

To evaluate the pharmacokinetics, safety and tolerability of GWP42006 compared with placebo, in the presence of other antiepileptic drugs (AEDs).

Condition or disease	Intervention/treatment	Phase
Epilepsy; Focal Seizures	Drug: GWP42006; Drug: Placebo	Phase 2

Detailed Description:

This is a double blind, randomized, placebo controlled, two-part study. Part A only will be described in this record.

Subjects who satisfy all inclusion and none of the exclusion criteria will begin a 14-day baseline observation period followed by a 14-day treatment period. Subjects will be required to attend six study visits. A follow-up phone call will take place four weeks after last dose.

Part A will enroll three groups of 10 subjects:

• Group 1 - subjects on inducer AEDs (and not on inhibitor AEDs)
• Group 2 - subjects on inhibitor AEDs (and not on inducer AEDs)
• Group 3 - subjects on AEDs that are neither inducers nor inhibitors.

In each of the three groups subjects will be randomized to receive, in a 4:1 ratio, GWP42006 400 mg twice daily or matching placebo. Pharmacokinetic (PK) profiles for GWP42006 and metabolites will be collected on the first and last day of treatment. Samples will also be collected 24h and 72h after the last day of treatment.

Subjects will be required to record a daily diary with information about their seizures, investigational medicinal product (IMP) and concomitant AED administration.

Study Design

• Study Type: Interventional (Clinical Trial)
• Actual Enrollment: 32 participants
• Allocation: Randomized
• Intervention Model: Parallel Assignment
• Masking: Triple (Participant, Investigator, Outcomes Assessor)
• Primary Purpose: Treatment
• Official Title: A Double Blind, Randomized, Placebo-controlled, Two-part Study to Investigate the Pharmacokinetics, Followed by Efficacy and Safety of GWP42006 as add-on Therapy in Patients With Inadequately Controlled Focal Seizures.
• Study Start Date: March 2015
• Actual Primary Completion Date: October 2015
• Actual Study Completion Date: November 2015

Arms and Interventions

Arm	Intervention/treatment
Experimental: Group 1a; Subjects on inducer AEDs will administer GWP42006.	Drug: GWP42006; Other Names: Cannabidivarin; CBDV
Active Comparator: Group 2a; Subjects on inhibitor AEDs will administer GWP42006.	Drug: GWP42006; Other Names: Cannabidivarin; CBDV
Experimental: Group 3a; Subjects on AEDs that are neither inducers nor inhibitors will administer GWP42006.	Drug: GWP42006; Other Names: Cannabidivarin; CBDV
Placebo Comparator: Group 1b; Matching placebo control for Group 1a.	Drug: Placebo
Placebo Comparator: Group 2b; Matching placebo control for Group 2a.	Drug: Placebo
Placebo Comparator: Group 3b; Matching placebo control for Group 3a.	Drug: Placebo

Outcome Measures

Primary Outcome Measures :

1. Pharmacokinetic parameters of GWP42006 and metabolites: Cmax, Cmin, tmax, AUC(0-t), AUC(0-inf) and t1/2, in the presence of other AEDs. [ Time Frame: Day 1 to Day 18 ]

Secondary Outcome Measures :

1. Safety and tolerability of GWP42006 (incidence of adverse events). [ Time Frame: Day -14 to Day 43 ]
2. The plasma concentration of concomitant AEDs. [ Time Frame: Day 1 and Day 15 ]

Eligibility Criteria

• Ages Eligible for Study: 18 Years to 65 Years (Adult, Older Adult)
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Criteria

For inclusion in Part A of the study patients must fulfil ALL of the following criteria:

• Male or female aged between 18 and 65 years, inclusive.
• Well-documented history of focal epilepsy, with focal seizures as the primary seizure type, compatible electroencephalogram and clinical history.
• Documented computerized tomography / magnetic resonance imaging that shows no progressive neurologic abnormality.
• Has focal seizures despite prior treatment with at least two AEDs (whether as monotherapies or in combination).

• Currently treated with one to three AEDs as follows:

  • Group 1 - subjects on inducer AEDs (and not on inhibitor AEDs)
  • Group 2 - subjects on inhibitor AEDs (and no on inducer AEDs)
  • Group 3 - subjects on AEDs that are neither inducers nor inhibitors.
• All medications or interventions for epilepsy (including ketogenic diet and any neurostimulation devices for epilepsy) must have been stable for two weeks prior to screening and the patient is willing to maintain a stable regimen throughout the study.
• Subject is willing to keep any factors expected to affect seizures stable (such as the level of alcohol consumption and smoking).

The patient may not enter Part A of the study if ANY of the following apply:

• Time of onset of epilepsy treatment is less than two years prior to enrolment.
• Episode(s) of status epilepticus during one year prior to screening.
• History of pseudo-seizures.
• Subject has clinically significant unstable medical conditions other than epilepsy.
• Subject has an illness in the four weeks prior to screening or randomization, other than epilepsy, which in the opinion of the investigator would affect seizure frequency.
• Subject has significantly impaired hepatic function at Visit 1.
• Active suicidal plan/intent in the past six months, or a history of suicide attempt in the last two years, or more than one lifetime suicide attempt.
• Subject is currently using or has in the past used recreational or medicinal cannabis, or cannabinoid based medications within the three months prior to screening and is unwilling to abstain for the duration for the study.
• Subject has taken St John's Wort in the last two weeks and/or is unwilling to abstain throughout the study.
• Subject has consumed grapefruit or grapefruit juice three days prior to randomization and/or unwilling to abstain in the three days prior to Visits A2 and A4.
• Any known or suspected hypersensitivity to cannabinoids, sesame oil or any of the excipients of the IMP(s).
• Subjects who have received an IMP within the 12 weeks prior to the screening visit.

Contacts and Locations

Locations

Czech Republic

Havířov, Czech Republic

Hradec Králové, Czech Republic

Rychnov nad Kněžnou, Czech Republic

Spain

Barcelona, Spain

United Kingdom

Birmingham, United Kingdom

Dundee, United Kingdom

Glasgow, United Kingdom

Great Yarmouth, United Kingdom

Stoke-on-Trent, United Kingdom

Sponsors and Collaborators

GW Research Ltd

Investigators

• Principal Investigator: Josemir W Sander, MD PhD FRCP; NIRH University College London

More Information

• Responsible Party: GW Research Ltd
• ClinicalTrials.gov Identifier: NCT02369471
• Other Study ID Numbers: GWEP1330 Part A; 2014-002594-11 ( EudraCT Number )
• First Posted: February 24, 2015
• Last Update Posted: June 6, 2016
• Last Verified: June 2016

Keywords provided by GW Research Ltd:

Cannabidivarin; CBDV; GWP42006

Additional relevant MeSH terms:

Seizures; Nervous System Diseases; Neurologic Manifestations